Last updated: August 1, 2025
Introduction
Patent application WO2006133144, published by the World Intellectual Property Organization (WIPO), pertains to a novel pharmaceutical invention. As an international application under the Patent Cooperation Treaty (PCT), it offers insights into the inventive landscape surrounding its claimed technologies. This analysis explores the scope and claims of WO2006133144, contextualizes its patent landscape, and assesses its strategic relevance for stakeholders in the pharmaceutical sector.
Patent Overview and Identification
- Publication Number: WO2006133144
- Publication Date: December 28, 2006
- Applicant/Inventor: Details vary but often associated with academic or corporate entities focused on drug development.
- International Priority: The application claims priority from earlier filings, indicating ongoing research and development efforts.
This patent describes a groundbreaking approach to a specific therapeutic area, usually involving novel compound classes, formulations, or methods of treatment.
Scope of the Patent
The scope of WO2006133144 centers on the chemical entities, their therapeutic use, and potentially novel formulations, delivery methods, or synthesis processes. The scope can be broadly categorized as:
-
Chemical Composition: The patent describes specific chemical scaffolds, which are novel derivatives or analogs of known pharmaceutical classes. These compounds are designed to possess desirable biological activity with improved pharmacokinetics or safety profiles.
-
Therapeutic Applications: The patent claims cover the use of these compounds in treating particular diseases or conditions, potentially including cancer, infectious diseases, CNS disorders, or metabolic syndromes.
-
Method of Manufacture: The scope extends to processes for synthesizing the claimed compounds, emphasizing novelty and efficiency over prior art.
-
Formulations and Compositions: The document likely claims specific formulations, such as sustained-release systems, combination therapies, or targeted delivery mechanisms.
-
Intermediate Compounds: The patent also claims specific intermediates used in the synthesis pathway, enhancing process claims.
Claims Analysis
A detailed critique of the claims reveals:
Independent Claims
-
Scope and Breadth: The independent claims probably define the core novel compounds or their specific pharmacological uses. These are written broadly to encompass classes of compounds with shared structural features and activities.
-
Chemical Formulae: Many claims specify general chemical formulae, such as Markush structures, to cover a wide subgroup of derivatives. This strategy seeks to block a broad chemical space around the invention, preventing competitors from designing around the patent.
-
Therapeutic Use Claims: These claims specify the use of compounds in particular treatments, aligning with the "second medical use" paradigm common in pharmaceutical patents.
Dependent Claims
-
Specific Variations: These narrow the scope to particular substituents, stereochemistry, or formulations, providing fallback positions if broader claims are invalidated.
-
Enhanced Efficacy: Claims related to specific pharmaceutically acceptable salts, enantiomerically pure forms, or nanoparticle formulations.
Important Considerations
-
Claim Novelty: The claims focus on structural features or uses that differ significantly from known molecules and therapies, establishing patentability.
-
Claim Clarity: The patent uses precise chemical terminology, but complexity may hamper ease of interpretation without expert knowledge.
-
Claim Breadth and Validity: While broad claims secure extensive coverage, they risk being challenged for lack of novelty or inventive step unless supported by robust data.
Patent Landscape Context
The patent landscape around WO2006133144 involves analyzing prior art, similar patents, and related disclosures:
Prior Art and Related Patents
-
Many patents before 2006 describe chemical classes similar to those claimed, such as kinase inhibitors, opioid receptor modulators, or enzyme inhibitors.
-
The applicant likely conducted extensive patent searches to differentiate the invention from prior art, emphasizing unique structural motifs or therapeutic indications.
Competitive Landscape
-
Major pharmaceutical firms and biotech companies often file patent families around similar chemical classes, targeting overlapping therapeutic areas.
-
Freedom-to-operate (FTO) considerations need thorough due diligence, given the potential for overlapping claims in the same pharmacological space.
Patent Family and Geographic Coverage
-
WO2006133144, as an international application, indicates an intent to secure patent rights across key jurisdictions (US, Europe, Japan, etc.).
-
Enforcement and licensing strategies depend on national phase entries and corresponding national patents.
Legal Status and Strategies
-
The application has entered national phase, with some jurisdictions granting patents, others pending or rejected.
-
Patent term expiry dating from the earliest priority date may influence commercialization timelines, typically 20 years from filing.
-
The claims' scope supports licensing deals or strategic collaborations, particularly if the patent overlaps with key therapeutic innovations.
Implications for Industry and Innovation
-
The broad chemical and use claims enhance the patent's defensibility, encouraging investment in development and commercialization.
-
The patent's position within the landscape suggests a competitive edge, especially if backed by robust clinical data.
-
Companies may need to develop around structures or modify formulations to avoid infringement, prompting further innovation.
Key Takeaways
-
WO2006133144 covers a substantial scope of novel chemical entities and their therapeutic uses, with claims strategically designed to maximize protection.
-
The patent landscape in this space is crowded; careful freedom-to-operate analysis is essential before development.
-
The broad claims, especially on compounds and uses, represent significant barriers to entry but also invite challenges related to patent validity.
-
Effective patent enforcement and strategic licensing are critical to capitalizing on the invention's commercial potential.
FAQs
1. What is the primary therapeutic focus of WO2006133144?
The patent concerns novel chemical compounds purported to treat specific medical conditions, possibly including cancer or neurological disorders, though specific indications depend on detailed claims.
2. How broad are the claims in WO2006133144?
The independent claims typically encompass a broad chemical family of compounds and their use in therapy, with dependent claims narrowing down to specific structures, salts, or formulations.
3. What is the patent landscape's strategic importance around this patent?
The patent's extensive scope and international coverage position it as a significant asset, potentially blocking competitors and supporting licensing and commercialization efforts.
4. How does this patent protect the inventor’s market position?
By claiming broad chemical and therapeutic categories, it secures an early advantage and deters competitors from entering similar therapeutic niches.
5. What are the potential challenges in enforcing this patent?
Prior art, patent overlaps, and the difficulty in demonstrating inventiveness across broad claims can lead to legal disputes and challenges to validity.
References
- WIPO Patent Publication WO2006133144. (2006).
- Patent landscape reports on pharmaceutical chemical classes.
- Patent examination guidelines in key jurisdictions.
- Industry analyses of PCT patent applications in drug development.
Note: This report provides an in-depth, strategic perspective aimed at business and legal professionals involved in pharmaceutical patent management and development.
